Drug Trial Radar · NCT07436728
A Study of TAK-505 in Adults With Solid Tumors
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
151
Planned (sponsor's estimate)
Start
May 11, 2026
Primary completion
Aug 18, 2030
Study completion Aug 18, 2030
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Feb 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Solid tumors occur when cells in an organ or tissue (for example in the lung or liver) start growing out of control (cancer) and form a lump or mass of cells. These solid cancers may grow very far in the general area where they started (called locally advanced) or may spread to other parts of the body (called metastatic), and doctors may not always be able to completely remove them with surgery (called unresectable). This study is a first in human (or FIH) study, which means that this is the first time that the medicine, TAK-505, is given to a smaller group of adults with solid tumors of certain cancer types, such as stomach cancer (gastric adenocarcinoma), cancer of the large bowel (colorectal cancer or CRC), lung cancer (non-small lung cell cancer or NSCLC) and cancer in the mouth, throat or voice box (head and neck squamous cell carcinoma or HNSCC). The main aims of this study are to learn how safe TAK-505 is, how well it works, how well adults with solid tumors tolerate it and to find the dose of TAK-505 that works best with the least side effects. Other aims are to learn how TAK-505 moves through the body (pharmacokinetics (PK)), if it can shrink or slow cancer (preliminary antitumor activity) and to find out if it causes the body's defense system to react to it (immunogenicity).
Conditions
- Malignant Solid Tumors
Interventions
TAK-505Drug
Participants will receive TAK-505 intravenously (IV)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: From initial dose until 28 days after infusion of the first cohort dose on Cycle 1 Day 1
- Phase 1 Dose Escalation: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Clinically Significant Laboratory Values and Vital SignsTime frame: From first dose of trial intervention through 30 days after administration of the last dose of trial intervention (up to approximately 52 months)
- Phase 2 Dose Expansion: Confirmed Overall Response Rate (ORR)Time frame: Up to end of study (up to approximately 52 months)
- Phase 2 Dose Expansion: Number of Participants With TEAEs, Clinically Significant Laboratory Values and Vital SignsTime frame: From first dose of trial intervention through 30 days after administration of the last dose of trial intervention (up to approximately 52 months)
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
UCI Health
Orange, California · Recruiting
University of California San Diego Medical Center, La Jolla
San Diego, California · Not yet recruiting
University of California San Francisco
San Francisco, California · Recruiting
H Lee Moffitt Cancer Center
Tampa, Florida · Recruiting
Univeristy of Minnesota
Minneapolis, Minnesota · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Cleveland Clinic Foundation
Cleveland, Ohio · Recruiting
Sarah Cannon Research Institute SCRI
Nashville, Tennessee · Recruiting
Tennessee Oncology
Nashville, Tennessee · Recruiting
Mary Crowley Cancer Center
Dallas, Texas · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
MD Anderson
Houston, Texas · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
NEXT Oncology
Fairfax, Virginia · Recruiting
Seattle Cancer Care Alliance
Seattle, Washington · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.